Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

e treatment of

hypertension and diabetic nephropathy. Findings from this study

also supported once-a-day oral dosing of PS433540 as the compound

successfully demonstrated its ability to block the angiotensin II-

induced blood pressure increase for 24 hours.

-- PS433540 demonstrated positive results in a multiple ascending dose

study. This safety and tolerability study was initially designed to

evaluate 14 days of daily dosing in healthy volunteers, at dose

levels of 50, 100, 250 and 500 mg of PS433540. As no safety or

tolerability issues were observed with any of these doses, the study

was expanded to include a 1,000 mg dose. As with previous lower

doses, there were no safety or tolerability issues observed with the

1,000 mg dose of PS433540.

-- Pharmacopeia announced that Bristol-Myers Squibb Company (BMS)

initiated a Phase 2 clinical trial with a p38 kinase inhibitor,

PS540446, that resulted from a collaborative research program between

the two companies. PS540446 is being evaluated for the oral treatment

of moderate to severe psoriasis.

-- Pharmacopeia announced that it earned a $1 million milestone payment

from Schering-Plough as the result of the initiation of a Phase 1

clinical trial in the United States for PS948115, a compound identified

from the collaboration between the two companies. The compound is

being evaluated as a potential treatment for respiratory disease.

Pharmacopeia is eligible to receive additional milestone payments for

PS540446 and PS948115 if the programs are advanced further in clinical

trials by BMS and Schering-Plough, respectively. The company will also

receive royalties on sales of any resulting therapeutic products

incorporating compounds derived from the progr
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Boston Scientific ... participate in the 2014 Credit Suisse Annual Healthcare Conference ... , AZ.  Dan Brennan , executive vice ... about the company beginning at approximately 8:00 a.m. PT ... A live webcast of the presentation and question and ...
(Date:10/30/2014)... 2014  Nektar Therapeutics (Nasdaq: NKTR ) ... ended September 30, 2014 on Thursday, November 6, 2014, ... Robin , president and chief executive officer, will host ... 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... audio-only Webcast of the conference call can be accessed ...
(Date:10/30/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced financial results for the third ... important corporate, commercial, regulatory and clinical development updates ... very pleased with the continued momentum and strong ... portfolio this quarter, especially the XIAFLEX franchise, which ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... in Combination with CRESTOR (rosuvastatin calcium) Improved LDL, HDL ... ... SEATTLE, May 31 New Phase III data showed,that in ... AstraZeneca,s CRESTOR(R) (rosuvastatin,calcium) led to greater improvements than the corresponding ...
... Annual Meeting -, SOUTH SAN FRANCISCO, ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... safety and,efficacy data from its ongoing Phase ... docetaxel and prednisone, the standard of care ...
Cached Medicine Technology:Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 2Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 3Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 4Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 2Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 3Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 4
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager ... help people save money through its innovative discount card ... drugs in the new health care system, the Paramount ... the relationship between consumers, businesses and the pharmacy industry. ... face today with medical costs is the rising price ...
(Date:10/30/2014)... Canada (PRWEB) October 30, 2014 Home ... area’s leading provider of non-medical, in-home senior care, is ... to increased brain health. , The study, performed by ... ages of 60 and 78 over a week-long period ... opposed to daily physical activity. By examining the structural ...
(Date:10/30/2014)... October 30, 2014 REV'D Provision Co. ... now available through a unique service called, The ... to empower the everyday athlete. The Feed has taken ... and created a system to pass that information on ... REV’D® is now available on The Feed!” says REV’D® ...
(Date:10/30/2014)... When it comes to heart disease, a new study finds ... they have symptoms that spell trouble. "The main danger ... more severe or advanced stage of heart disease, there are ... Fulbright Scholar and research fellow at the Harvard School of ... and Stroke Foundation of Canada. In the study, researchers ...
(Date:10/30/2014)... a low-carb, high-fat diet could help control epilepsy that ... A review of five studies found that a ... like bacon, eggs, heavy cream, butter, fish and green ... doesn,t improve with medication. "We need new treatments ... seizures are not stopped by medications," study co-author Dr. ...
Breaking Medicine News(10 mins):Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... , TUESDAY, June 29 (HealthDay News) -- Scientists report ... older women by causing certain genetic mutations. The study ... National Cancer Institute. . Previous research has indicated that ... develop colorectal cancer than those who never smoked, according to ...
... ... employers who want to provide health benefits and control costs., , ... Minneapolis, MN (PRWEB) June 29, 2010 ... largest independent insurance and employee benefits brokers in the Midwest, to offer customized defined ...
... ... Symptom Checker, a new online tool to help users evaluate their child,s symptoms. The tool ... ... if your child develops a fever, cough, vomiting, rash, sore throat or head injury? A ...
... HealthDay Reporter , TUESDAY, June 29 (HealthDay News) -- Type ... that continuously monitored their blood sugar levels had better control ... clinical trial finds. , , Researchers divided 485 people ... multiple daily insulin injections and tested their blood sugar throughout ...
... the Ohio State University Comprehensive Cancer Center-Arthur G. ... Institute (OSUCCC-James) have discovered how a substance that ... can block the proliferation of cancer cells. ... may have anticancer effects and other health benefits, ...
... powerful and highly addictive psychostimulant that is toxic to ... many parts of the United States. The National Institute ... Americans have tried methamphetamine, while more than 1.4 million ... the drug can lead to devastating medical, psychological and ...
Cached Medicine News:Health News:Bloom Health and Christensen Group Partner Together to Deliver Innovative Solution 2Health News:AAP Offers New Online Pediatric Symptom Checker on HealthyChildren.org 2Health News:Insulin Pump With Blood Sugar Sensor May Improve on Injections 2Health News:Insulin Pump With Blood Sugar Sensor May Improve on Injections 3Health News:Study shows how dietary supplement may block cancer cells 2Health News:Dental school gets $1.86 million from NIH for study of methamphetamine's effect on oral health 2
...
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
It is lightweight and portable headlight option for office exam room. It offers complete comfort and portability....
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Medicine Products: